Abstract
Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have